Report for: No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis

Title	No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis
Published in	PLOS ONE, December 2013
DOI	10.1371/journal.pone.0081997
Pubmed ID	24367497
Authors	Julia L. Marcus, David V. Glidden, Kenneth H. Mayer, Albert Y. Liu, Susan P. Buchbinder, K. Rivet Amico, Vanessa McMahan, Esper Georges Kallas, Orlando Montoya-Herrera, Jose Pilotto, Robert M. Grant
Abstract	Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We evaluated potential risk compensation using biomarkers of sexual risk behavior.

X Demographics

The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.

Type	Count	As %
Members of the public	14	88%
Practitioners (doctors, other healthcare professionals)	2	13%

Mendeley readers

The data shown below were compiled from readership statistics for 276 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Readers by professional status	Count	As %
Student > Master	58	21%
Researcher	40	14%
Student > Bachelor	30	11%
Student > Ph. D. Student	24	9%
Student > Doctoral Student	22	8%
Other	55	20%
Unknown	47	17%

Readers by discipline	Count	As %
Medicine and Dentistry	96	35%
Social Sciences	31	11%
Psychology	22	8%
Nursing and Health Professions	19	7%
Agricultural and Biological Sciences	14	5%
Other	31	11%
Unknown	63	23%

PLOS